FDA Warns of Hidden PDE5 Inhibitors and Anabolic Steroids in Over-the-Counter Male Supplements

FDA Warns of Hidden PDE5 Inhibitors and Anabolic Steroids in Over-the-Counter Male Supplements

The U.S. Food and Drug Administration updated its safety communication on September 18, 2024, reporting the detection of undeclared sildenafil, tadalafil, and anabolic steroids in multiple male enhancement and testosterone dietary supplements [1][2]. Laboratory testing identified these hidden pharmaceutical ingredients in products marketed as “all natural.” The findings document continued adulteration within this product category despite manufacturer claims.

The update incorporates recent laboratory results and adverse event reports submitted through the agency’s MedWatch program. It expands the FDA’s publicly available list of tainted sexual enhancement products.

What this means

The data indicate that products labeled as dietary supplements for male enhancement or testosterone support may contain active pharmaceutical ingredients not disclosed on labeling. This pattern aligns with prior FDA surveillance showing that PDE5 inhibitors and anabolic steroids appear repeatedly in tested samples. The alert reflects the agency’s post-market oversight approach rather than pre-market approval of these products.

FDA Laboratory Findings

FDA testing conducted as part of ongoing surveillance identified undeclared sildenafil and tadalafil, which are PDE5 inhibitors, along with anabolic steroids in multiple over-the-counter male supplements on September 18, 2024 [2]. The agency has maintained a public list of such tainted products for several years.

Documented Health Risks

The FDA associated the hidden PDE5 inhibitors with severe hypotension when taken with nitrates, as well as elevated risks of heart attack, stroke, and priapism [1]. The presence of anabolic steroids was linked to hepatotoxicity in the safety alerts.

Regulatory Context and Surveillance Scope

The National Institutes of Health resource on dietary supplements states that the FDA does not evaluate these products for safety or efficacy before they reach the market [3]. An August 2024 overview of FDA activities confirmed that surveillance continues to identify adulterated supplements despite repeated warnings to industry.

Limitations

FDA testing covers only a fraction of available products on the market. Data relies on voluntary adverse event reporting which may underrepresent total incidents. Communication is U.S.-specific and does not address international regulatory actions or long-term population-level exposure effects. No new clinical trial data is presented.